GlassScriptPhysician profile
Aleli C Masajo
NPI 1396912762
$2,714.53
in general payments reported to CMS, 2019-2025
20 companies · $464 in 2025
The $464 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $258 · 2021: $458 · 2022: $354 · 2023: $594 · 2024: $411 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $546.11 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $367.31 | 2022-2024 | |
| Corium, LLC | $333.65 | 2021-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $214.61 | 2020-2022 | |
| Tris Pharma INC | $185.37 | 2020-2025 | Onyda Xr |
| Collegium Pharmaceutical, INC. | $173.10 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $153.11 | 2019-2024 | Vaxneuvance, Vaxelis, Vaqta |
| Sobi, INC | $108.31 | 2021-2023 | |
| Cipher Pharmaceuticals US LLC | $105.03 | 2025 | Spinosad, Natroba |
| Seqirus USA INC | $98.56 | 2022-2025 | Flucelvax |
| Pfizer INC. | $90.51 | 2021-2023 | |
| Cranial Technologies, INC | $82.85 | 2021-2024 | Doc Band |
| Biomarin Pharmaceutical INC. | $63.24 | 2025 | Voxzogo 1.2mg |
| Supernus Pharmaceuticals, INC. | $45.81 | 2021-2022 | |
| Shire North American Group INC | $33.73 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30.12 | 2019-2025 | Pediarix, Bexsero, Penmenvy |
| Noven Therapeutics, LLC | $24.64 | 2025 | Xelstrym |
| Phadia US INC. | $22.98 | 2025 | Immunocap |
| Alk-Abello, INC | $19.45 | 2023 | Odactra, Ragwitek, Grastek |
| Vertical Pharmaceuticals, LLC | $16.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleli Masajo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.